Hyperprolactinaemia – a problem in patients from the reproductive period to the menopause

Hyperprolactinaemia especially affects women in reproductive age (90/100,000) but also often is diagnosed in menopause age and leads to disturbances in functioning of LH-RH neurons and, as a consequence, to a decrease of FSH and LH, which causes inhibition of oestradiol production. Prolactin is a peptide hormone, phylogenetically one of the oldest, stimulating cells of various organs, which is produced and secreted mainly by lactotrophic acidophilic cells of the anterior lobe of the pituitary. It influences the increase in the mass of the mammary glands, and stimulation and maintenance of lactation after delivery. There are a number of factors apart of pregnancy, delivery, and lactation than can influence secretion of the hormone in other physiological and pathological circumstances, like high-protein diet, stress, REM sleep, or neoplastic tumours, inflammatory diseases, chronic systematic diseases, thyroid hormonal changes, and drug intake. The purpose of this review is to summarise the current knowledge regarding the proper diagnosis and possible influence of hyperprolactinaemia on fertility and menopause symptoms and current treatment methods

[1]  R. Hovey,et al.  Regulation and localization of vascular endothelial growth factor within the mammary glands during the transition from late gestation to lactation. , 2016, Domestic animal endocrinology.

[2]  D. Iacovazzo,et al.  Treatment of hyperprolactinemia in post-menopausal women: pros , 2015, Endocrine.

[3]  C. Benbassat,et al.  Women with prolactinomas presented at the postmenopausal period , 2014, Endocrine.

[4]  M. Gasperi,et al.  Effect of Cabergoline on Metabolism in Prolactinomas , 2013, Neuroendocrinology.

[5]  V. Guarnotta,et al.  Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels , 2013, Clinical endocrinology.

[6]  E. Baracat,et al.  Hyperprolactinemia changes the sulfated glycosaminoglycan amount on the murine uterus during the estrous cycle. , 2013, Fertility and sterility.

[7]  R. Ersoy,et al.  Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma , 2013, Endocrine.

[8]  U. Kaiser.  Hyperprolactinemia and infertility: new insights. , 2012, The Journal of clinical investigation.

[9]  W. Kuczyński,et al.  [Polish Gynecological Society and Polish Society for Reproductive Medicine recommendations for the diagnosis and treatment of infertility]. , 2012, Ginekologia polska.

[10]  E. Menis,et al.  High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas , 2011, Pituitary.

[11]  Victor M Montori,et al.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[12]  R. El Dib,et al.  Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis , 2011, Pituitary.

[13]  Grażyna Jarząbek-Bielecka,et al.  Analiza stężeń prolaktyny u dziewcząt bez cech endokrynopatii z zaburzeniami miesiączkowania i stresem w wywiadzie , 2010 .

[14]  C. McCudden,et al.  Comparison of multiple methods for identification of hyperprolactinemia in the presence of macroprolactin. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[15]  H. Fideleff,et al.  Prolactinoma in Children and Adolescents , 2009, Hormone Research in Paediatrics.

[16]  D. Seriwatanachai,et al.  Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization , 2009, Journal of cellular biochemistry.

[17]  K. Safranow,et al.  Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia. , 2009, Metabolism: clinical and experimental.

[18]  D. Seriwatanachai,et al.  Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. , 2008, Bone.

[19]  W. Jeske.  [The main reasons behind variability in detection of prolactin and causes of true or apparent discordance with clinical state]. , 2008, Endokrynologia Polska.

[20]  J. Schlechte,et al.  The effects of hyperprolactinemia on bone and fat , 2008, Pituitary.

[21]  S. Bhasin,et al.  Sexual dysfunction in men and women with endocrine disorders , 2007, The Lancet.

[22]  A. Lewiński,et al.  [Hyperprolactinemia: causes, diagnosis, and treatment]. , 2006, Endokrynologia Polska.

[23]  P. Cappabianca,et al.  Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas , 2006, Clinical endocrinology.

[24]  A. Colao,et al.  Advances in the treatment of prolactinomas. , 2006, Endocrine reviews.

[25]  P. Crosignani.  Current treatment issues in female hyperprolactinaemia. , 2006, European journal of obstetrics, gynecology, and reproductive biology.

[26]  W. Zgliczyński,et al.  [Hyperprolactinaemia--pitfalls in PRL assessment]. , 2005, Endokrynologia Polska.

[27]  Thomas P. Smith,et al.  Clinical relevance of macroprolactin , 2005, Clinical endocrinology.

[28]  C. Jaspers,et al.  Control of prolactin secretion , 1990, Klinische Wochenschrift.

[29]  A. Tuzcu,et al.  Insulin sensitivity and hyperprolactinemia , 2003, Journal of endocrinological investigation.

[30]  R. Abs,et al.  Hyperprolactinemia: pathophysiology and management. , 2003, Treatments in endocrinology.

[31]  N. Hattori.  Macroprolactinemia: a new cause of hyperprolactinemia. , 2003, Journal of Pharmacological Sciences.

[32]  F. Casanueva,et al.  Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. , 2002, European journal of endocrinology.

[33]  A. Colao,et al.  Dopamine receptor agonists for treating prolactinomas , 2002, Expert opinion on investigational drugs.

[34]  E. Giolo,et al.  Pregnancy in Hyperprolactinemic Infertile Women Treated with Vaginal Bromocriptine: Report of Two Cases and Review of the Literature , 2001, Gynecologic and Obstetric Investigation.

[35]  J. Wass,et al.  The effect of the menopause on prolactin levels in patients with hyperprolactinaemia , 2001, Clinical endocrinology.

[36]  Jean Logan,et al.  Brain dopamine and obesity , 2001, The Lancet.

[37]  G. Nagy,et al.  Prolactin: structure, function, and regulation of secretion. , 2000, Physiological reviews.

[38]  M. Czarnecki,et al.  [The method of treatment of functional evident hyperprolactinemia in sterile women]. , 1998, Ginekologia polska.

[39]  Kiyohisa Takahashi,et al.  The 24‐hour Rhythms in Plasma Growth Hormone, Prolactin and Thyroid Stimulating Hormone: Effect of Sleep Deprivation , 1995, Journal of neuroendocrinology.

[40]  J. Webster,et al.  A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea , 1994, The New England journal of medicine.

[41]  P. Hardiman,et al.  Vaginal bromocriptine--clinical and biochemical effects. , 1992, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[42]  R. Croughs,et al.  [Hyperprolactinemia and prolactinomas]. , 1991, Nederlands tijdschrift voor geneeskunde.

[43]  L. Pedneault,et al.  Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas. , 1990, The Journal of clinical endocrinology and metabolism.

[44]  E. Cutié,et al.  Prolactin inhibits the steroidogenesis in midfollicular phase human granulosa cells cultured in a chemically defined medium. , 1988, Fertility and sterility.

[45]  P. C. Jackson,et al.  Osteoporosis and amenorrhea in young women. , 1987, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[46]  M. Kathol,et al.  Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. , 1987, The Journal of clinical endocrinology and metabolism.

[47]  A. Klibanski,et al.  Increase in bone mass after treatment of hyperprolactinemic amenorrhea. , 1986, The New England journal of medicine.

[48]  J. Schenker,et al.  Transient hyperprolactinemia: a correctable cause of idiopathic female infertility. , 1983, The Journal of clinical endocrinology and metabolism.

[49]  B. Sherman,et al.  Bone density in amenorrheic women with and without hyperprolactinemia. , 1983, The Journal of clinical endocrinology and metabolism.

[50]  M. Sowa,et al.  Relationship among the status of the human oocyte, the 17 beta-estradiol concentration in the antral fluid and the follicular size. , 1983, Endocrinologia japonica.

[51]  M. Ono,et al.  Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17 beta-estradiol in the human ovary. , 1982, The Journal of clinical endocrinology and metabolism.

[52]  P. Ylöstalo,et al.  Metoclopramide-induced hyperprolactinemia impairs ovarian follicle maturation and corpus luteum function in women. , 1982, The Journal of clinical endocrinology and metabolism.

[53]  J. Szücs,et al.  Decreased bone density in hyperprolactinemic women. , 1981, The New England journal of medicine.

[54]  K. McNatty,et al.  Relationship between plasma prolactin and the endocrine microenvironment of the developing human antral follicle. , 1979, Fertility and sterility.

[55]  G. Tolis,et al.  Prolactin and Deficient Luteal Function , 1979, Obstetrics and gynecology.

[56]  S. Yen,et al.  Effects of oral contraceptive steroids on pituitary prolactin secretion. , 1976, Contraception.

[57]  D. Parker,et al.  Relation of sleep-entrained human prolactin release to REM-nonREM cycles. , 1974, The Journal of clinical endocrinology and metabolism.